Hematological Malignancies
133
21
31
53
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
21 trials with published results (16%)
Research Maturity
53 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.8%
9 terminated out of 133 trials
85.5%
-1.0% vs benchmark
8%
11 trials in Phase 3/4
40%
21 of 53 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 53 completed trials
Clinical Trials (133)
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
Durvalumab and Tremelimumab for Pediatric Malignancies
Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)